Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis

Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis

Abstract Background This study is to investigate the effects of zoledronic acid (ZA) on TSC2-null cell proliferation and on the tumor progression and recurrence in mouse models of lymphangioleiomyomatosis (LAM). Methods Subcutaneous mouse models and LAM mouse models were established. Immunohistochem...

Full description

Bibliographic Details
Main Authors: Dandan Zhao, Jing Wu, Yinjuan Zhao, Wei Shao, Qi Cheng, Xiaoyan Shao, Xianwen Yuan, Juan Ye, Jianpu Gao, Meiling Jin, Chaojun Li, Xiaolin Chen, Yue Zhao, Bin Xue
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Cancer Cell International
Subjects:
Lymphangioleiomyomatosis
MTOR
Zoledronic acid (ZA)
YAP
Autophagy
Online Access:https://doi.org/10.1186/s12935-020-1131-4

Internet

https://doi.org/10.1186/s12935-020-1131-4

Similar Items